MedTrace Logo

AZD6280 Multiple Ascending Dose Study

NCT00681317 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2010-12-09

No results posted yet for this study

Summary

This is a study to evaluate safety, tolerability, PK and PD effects of orally administered AZD6280 after single and repeated ascending doses.

Conditions

  • Healthy Volunteer

Interventions

DRUG

AZD6280

oral

Sponsors & Collaborators

Principal Investigators

  • Sylvan J. Hurewitz, MD · AstraZeneca Clinical Pharmacology Unit, US

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2008-07-31
Completion
2008-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00681317 on ClinicalTrials.gov